IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JIA ET AL. APPLICANT: SERIAL NO.: 10/817,330

EXAMINER:

APRIL 02, 2004 ART UNIT: 1655 FILED:

CONFIRMATION NO.: 1136 TITLE: FORMULATION OF DUAL

CYCLOXYGENASE (COX) AND LIPOXYGENASE (LOX) INHIBITORS FOR MAMMAL SKIN CARE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- within three months of the filing date of a national application (other than a CPA (a) under 37 CFR § 1.53(d));
- within three months of the date of entry of the national stage as set forth in 37 (b) CFR § 1.491 in an international application;
- before the mailing of a first Office Action of the merits; or (c)
- before the mailing of a first Office Action after the filing of a request for (d) continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Rosemary Kellogg, #39,7

Swanson & Bratschun, L.L.

1/45 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129

Telephone: (303) 268-0066 Facsimile: (303) 268-0065

S:\ClientFolders\UniGen Pharmaceuticals\UNI26\UTILITY\IDS08.doc

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	ATTY. DOCKET NO. UNI.26	SERIAL NO. 10/817,330
	OFFICE	APPLICANT	
List of Inform	ation Cited by Applicant	JIA ET AL.	
Page 1 of 1		FILING DATE	GROUP
		APRIL 02, 2004	1655

	U.S. PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF	·					
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						

	FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRAN S?
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	AR	CHEN et al., Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation (June 1, 2000) Biochemical Pharmacology 59:1445-1447		
	AS	CHUNG et al., Pharmacological Effects of Methanolic Extract from the Root of Scutellaria baicalensis and its Flavonoids on Human Gingival Fibroblast (April 1995) Planta Med. 61:150-153		
	AAA	KUBO et al., Studies on Scutellariae Radix. VII.1) Anti-arthritic and Anti-inflammatory Actions of Methanolic Extract and Flavonoid Components from Scutellariae Radix (1984) Chemical and Pharmaceutical Bulletin 32(7):2724-2729		
	AAB			
	AAC			
	AAD			
XAMINER		DATE CONSIDERED		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

S:\ClientFolders\UniGen Pharmaceuticals\UNI26\UTILITY\IDS08.doc